Immunotherapy is a type of cancer treatment that boosts the immune system to fight cancer by helping it to recognize and attack tumor cells. While this therapeutic strategy continues to revolutionize the treatment of an increasing number of tumor types, it fails to achieve clinical responses in many patients and does not yield benefit in the treatment of many cancers. There is therefore an unmet clinical need to identify predictive biomarkers of response for selecting those patients who would most likely benefit from immune-based therapies.
A pan-cancer platform to help guide patient selection for personalized immunotherapy
Immunotherapy is a type of cancer treatment that boosts the immune system to fight cancer by helping it to recognize and attack tumor cells. While this therapeutic strategy continues to revolutionize the treatment of an increasing number of tumor types, it fails to achieve clinical responses in many patients and does not yield benefit in the treatment of many cancers. There is therefore an unmet clinical need to identify predictive biomarkers of response for selecting those patients who would most likely benefit from immune-based therapies.